Lapatinib in Endocrine-Resistant Metastatic Breast Cancer.
Latest Information Update: 17 Jul 2023
At a glance
- Drugs Lapatinib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 20 Oct 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 28 Jun 2011 Planned end date changed from 1 Dec 2010 to 1 Jun 2012 as reported by ClinicalTrials.gov.
- 14 Jun 2010 Planned end date changed from 1 Mar 2010 to 1 Dec 2010 as reported by ClinicalTrials.gov.